Testing liposomal curcumin for multiple myeloma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a special form of curcumin (the ingredient in turmeric) wrapped in tiny fat particles to see if it's safe and helpful for people with multiple myeloma that has come back or not responded to other treatments. It may offer an option when standard therapies are no longer effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back after treatment or did not respond to at least one prior therapy
- You have tried at least one immunomodulatory drug (like lenalidomide or pomalidomide), one proteasome inhibitor (like bortezomib or carfilzomib), and one anti-CD38 drug (like daratumumab or isatuximab)
- No standard treatment options are available to you
- You are able to take oral medications and have adequate organ function (bone marrow, liver, kidneys)
- You have measurable signs of myeloma, such as certain levels of M-protein or free light chains in blood or urine
- You are not pregnant or breastfeeding, and agree to use effective birth control if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HuL001 combined with lenalidomide and dexamethasone for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. It aims to see if this combination can help when other options have failed.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.
This study tests a new drug, BMS-986453, for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to see if it is safe and works against the cancer.
This trial tests a new treatment called BCD-248 for people whose multiple myeloma has come back or stopped responding to at least two prior treatments. It aims to see if it is safe and effective.
This trial tests two new medicines, talquetamab and belantamab mafodotin, for people whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if this combination can shrink the cancer and help you feel better.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.